Company Overview and News

 
Brian Gaynor: Cannabis stocks don't take long to get high

2017-05-12 nzherald.co.nz
Global sharemarkets are going to pot as a large number of marijuana companies have listed in recent years, including on the Australian sharemarket.

 
Botanix makes ASX debut

2016-07-15 businessnews.com.au
Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.

 
Medical dermatology company Botanix Pharmaceuticals lists on Australian Securities Exchange (ASX)

2016-07-15 biospectrumasia
It's fast, free and easy to sign in with Facebook, Google, or Yahoo. Be connected on your terms - we won't share anything without your permission

 
Botanix eyes synthetic medicinal marijuana

2016-06-29 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Botanix eyes synthetic medicinal marijuana

2016-06-29 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
 
 
Response to ASX Price Query

2016-05-12 asx.com.au

 
Appendix 4C - quarterly

2016-04-29 asx.com.au

 
Bone Medical in dermatology move

2016-03-21 businessnews.com.au
Listen to podcasts covering breaking news, items of interest and our Success & Leadership Series events. A wide range of topics covered by our well renowned reporters and WA business leaders. Subscribe on iTunes for updates as they happen. Click here for more

 
Trading Halt

2016-03-18 asx.com.au

 
Bone Medical Ltd set to reveal acquisition

2016-03-17 proactiveinvestors.com.au
Bone Medical Ltd (ASX:BNE) has some interesting news on the horizon, in the form of an acquisition. The ASX has granted the company a trading halt to prepare, with its shares placed in pre-open. The halt will remain in place until the opening of trade on Tuesday 22nd March 2016, or earlier if an announcement is made to the market.

 
Half Yearly Report and Accounts

2016-02-19 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...